sapiencetherapeutics.comHealthcare / BioTech & PharmaFounded: 2015Funding to Date: $63.88MM
Sapience Therapeutics develops peptide-based oncology treatments and therapies by targeting intracellular interactions.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
05/31/2022 | Series B-1 | $12.75MM | $xx.xx | $289.73MM | NexPoint, Bristol Myers Squibb, Eshelman Ventures, Kingdon Capital | |
Price per Share
$xx.xx
Shares Outstanding
5,059,524
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
1000.0
Key Investors
NexPoint, Bristol Myers Squibb, Eshelman Ventures, Kingdon Capital
|
||||||
05/31/2022 | Series B | $28.25MM | $xx.xx | $289.73MM | NexPoint, Bristol Myers Squibb, Eshelman Ventures, Kingdon Capital | |
Price per Share
$xx.xx
Shares Outstanding
7,847,222
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
1000.0
Key Investors
NexPoint, Bristol Myers Squibb, Eshelman Ventures, Kingdon Capital
|
||||||
07/12/2016 | Series A | $22.88MM | $xx.xx | $76.28MM | Eshelman Ventures, Celgene Corporation, TaiAn Technologies Corporation, Healthlink Capital, Columbia University | |
Price per Share
$xx.xx
Shares Outstanding
16,345,464
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
1000.0
Key Investors
Eshelman Ventures, Celgene Corporation, TaiAn Technologies Corporation, Healthlink Capital, Columbia University
|